| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2649 | 2016 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... International Journal of Gynecological Cancer 29 (4), 728-760, 2019 | 1278 | 2019 |
| Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, ... Annals of Oncology 28, iv72-iv83, 2017 | 903 | 2017 |
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial AM Oza, D Cibula, AO Benzaquen, C Poole, RHJ Mathijssen, GS Sonke, ... The lancet oncology 16 (1), 87-97, 2015 | 650 | 2015 |
| A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms P Harter, J Sehouli, D Lorusso, A Reuss, I Vergote, C Marth, JW Kim, ... New England Journal of Medicine 380 (9), 822-832, 2019 | 575 | 2019 |
| Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission … P Harter, J Sehouli, A Reuss, A Hasenburg, G Scambia, D Cibula, ... International Journal of Gynecological Cancer 21 (2), 289-295, 2011 | 399 | 2011 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 332 | 2021 |
| Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F … J Schwarz-Dose, M Untch, R Tiling, S Sassen, S Mahner, S Kahlert, ... Journal of Clinical Oncology 27 (4), 535-541, 2009 | 271 | 2009 |
| Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group A Du Bois, N Ewald-Riegler, N De Gregorio, A Reuss, S Mahner, ... European journal of cancer 49 (8), 1905-1914, 2013 | 268 | 2013 |
| Adjuvant therapy in lymph node–positive vulvar cancer: The AGO-CaRE-1 study S Mahner, J Jueckstock, F Hilpert, P Neuser, P Harter, N de Gregorio, ... Journal of the National Cancer Institute 107 (3), dju426, 2015 | 252 | 2015 |
| European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer MHM Oonk, F Planchamp, P Baldwin, M Bidzinski, M Brännström, ... International Journal of Gynecological Cancer 27 (4), 832-837, 2017 | 228 | 2017 |
| TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7) A Reuss, A Du Bois, P Harter, C Fotopoulou, J Sehouli, G Aletti, F Guyon, ... International Journal of Gynecological Cancer 29 (8), 1327-1331, 2019 | 191 | 2019 |
| Safety and dose modification for patients receiving niraparib JS Berek, UA Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, ... Annals of Oncology 29 (8), 1784-1792, 2018 | 188 | 2018 |
| Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial JM Del Campo, UA Matulonis, S Malander, D Provencher, S Mahner, ... Journal of Clinical Oncology 37 (32), 2968-2973, 2019 | 174 | 2019 |
| Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer S Mahner, S Schirrmacher, W Brenner, L Jenicke, CR Habermann, N Avril, ... Annals of oncology 19 (7), 1249-1254, 2008 | 167 | 2008 |
| C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma S Mahner, C Baasch, J Schwarz, S Hein, L Wölber, F Jänicke, ... British journal of cancer 99 (8), 1269-1275, 2008 | 165 | 2008 |
| Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial J Pfisterer, CM Shannon, K Baumann, J Rau, P Harter, F Joly, J Sehouli, ... The Lancet Oncology 21 (5), 699-709, 2020 | 162 | 2020 |
| Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP) N Duesing, J Schwarz, M Choschzick, F Jaenicke, F Gieseking, R Issa, ... Archives of gynecology and obstetrics 286, 1549-1554, 2012 | 160 | 2012 |
| Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium E Obermayr, DC Castillo-Tong, D Pils, P Speiser, I Braicu, T Van Gorp, ... Gynecologic oncology 128 (1), 15-21, 2013 | 148 | 2013 |
| Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment L Woelber, C Eulenburg, M Choschzick, A Kruell, C Petersen, F Gieseking, ... International Journal of Gynecological Cancer 22 (3), 503-508, 2012 | 145 | 2012 |
Andreas du BoisProfessor für Gynäkologie, Gutenberg Universität Mainz, Kliniken Essen MitteВерификована је имејл адреса на kem-med.com